Recent News

• 08.06.2026 - Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium
• 08.04.2026 - Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile
• 07.21.2026 - Harmony Biosciences To Report Second Quarter 2026 Financial Results On August 4, 2026
• 07.16.2026 - Harmony Biosciences Preannounces Record Quarterly Revenue for Q2 2026, Reaffirms Full-Year 2026 Revenue Guidance, and Announces CFO Transition
• 06.11.2026 - Harmony Biosciences Announces Poster Presentations at 2026 SLEEP Annual Meeting
• 03.04.2026 - Harmony Biosciences to Participate in Upcoming Investor Conferences
• 02.24.2026 - Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
• 02.17.2026 - Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX® (pitolisant) for the Treatment of Cataplexy in Pediatric Narcolepsy
• 02.10.2026 - Harmony Biosciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
• 01.12.2026 - Harmony Biosciences Guides to Over $1 Billion in WAKIX® Revenue in 2026; Advancing Robust Late-Stage Pipeline With Potential for Long-term Value Creation

Recent Filings

• 08.04.2026 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 08.04.2026 - 8-K Current report
• 08.04.2026 - EX-99.1 EX-99.1
• 07.31.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 07.28.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 07.22.2026 - 3 Initial statement of beneficial ownership of securities
• 07.16.2026 - 8-K Current report
• 07.16.2026 - EX-99.1 EX-99.1
• 07.02.2026 - 144 Report of proposed sale of securities
• 06.30.2026 - 144 Report of proposed sale of securities